Common immunization routes for coronavirus disease 2019 (COVID-19) vaccine candidates range from intramuscular, nasal and oral to intradermal.
Now, scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.
The study, published on the pre-print bioRxiv* server, shows another potential effective route to administer vaccines against SARS-CoV-2, the virus that causes COVID-19. Finding more ways to introduce vaccines can help combat the pandemic.
As the pandemic continues to spread, many countries have already rolled out their immunization plans. To date, there are about 251 vaccines developed against SARS-CoV-2 infection. Of these, 70 vaccines are undergoing human trials to determine safety and efficacy.
Most of the COVID-19 vaccines developed are administered intramuscularly, while others can be given orally, intradermally, subcutaneously, and intranasally.
Epicutaneous immunization involves the introduction of biological material, drugs, or vaccines into the skin by shallow and bloodless piercing with small needles…